At CSI, our commitment to patients, physicians and hospitals doesn’t end with delivering unique technology. Our team collaborates with leading experts and encourages policy organizations to support patient access and appropriate reimbursement for high-quality interventional treatments for PAD and CAD.
CSI is a leader in advocating for the introduction and the continuance of Medicare reimbursement codes for treatment of vascular disease. We continually work with The Centers for Medicare and Medicaid Services (CMS) to introduce new codes to keep up with new technology and provide fair payments for relevant value-based codes.
We are currently working with CMS and elected representatives to establish Medicare coverage to mandate PAD screenings for at-risk beneficiaries and other initiatives to reduce racial disparities in treatment access. Learn more about our Healthcare Policy initiatives.
Through regulatory and legislative efforts now and in the future, CSI works to deliver on our promise to support physicians and hospitals.
The CSI team is committed to assisting healthcare policymakers and healthcare providers in evaluating the economic impact of utilizing orbital atherectomy technology.
Analysis of cost-effectiveness of treatment with orbital atherectomy
CSIQ® is the official professional education program of Cardiovascular Systems, Inc. Our goal is for you to use this information to better understand the prevalence of arterial calcium and how to treat it using our Orbital Atherectomy Systems. From group courses taught by leading orbital atherectomy experts to personalized, one-on-one proctorships, CSIQ® demonstrates the value and procedural efficiency of our Orbital Atherectomy Systems. Clinical data that underscore the safety, efficacy and long-term durability of the devices is also provided.